Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

The p53 pathway has been shown to mediate cellular stress responses; p53 can initiate DNA repair, cell-cycle arrest, senescence and, importantly, apoptosis. These responses have been implicated in an individual's ability to suppress tumour formation and to respond to many types of cancer therapy. Here we focus on how best to use knowledge of this pathway to tailor current therapies and develop novel ones. Studies of the genetics of p53 pathway components - in particular p53 itself and its negative regulator MDM2 - in cancer cells has proven useful in the development of targeted therapies. Furthermore, inherited single nucleotide polymorphisms in p53 pathway genes could serve a similar purpose.

Original publication

DOI

10.1038/nrd2656

Type

Journal article

Journal

Nat Rev Drug Discov

Publication Date

12/2008

Volume

7

Pages

979 - 987

Keywords

Animals, Antineoplastic Agents, Apoptosis, Clinical Trials as Topic, DNA Damage, DNA, Neoplasm, Disease Models, Animal, Humans, Neoplasms, Tumor Suppressor Protein p53